<DOC>
	<DOCNO>NCT02390466</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability VAC-3S control HIV patient receive standard care antiretroviral treatment .</brief_summary>
	<brief_title>Open-label , Phase I/IIa Study VAC-3S HIV-1 Patients Who Showed Immune Response VAC-3S During IVVAC-3S/P1</brief_title>
	<detailed_description />
	<criteria>HIV1 infect patient , Age 18 60 year , ART ( Anti Retroviral Therapy ) initiation ≥ 1 year ago , Plasma HIV RNA ≤ 200 copies/ml past 12 month , Plasma HIV RNA ≤ 50 copies/ml screen visit , CD4+ T cell count ≥ 200 cells/mm3 , Nadir CD4+ T cell count ≥ 100 cells/mm3 , Contraception woman childbearing potential , A total anti3S titer ≥ 20 A.U . time point IVVAC3S/P1 clinical trial , Per protocol subject complete IVVAC3S/P1 study . Patient affiliate social security system , Patient understand protocol design provide sign write informed consent form , Patient willing capable cooperate extent degree require protocol , Patient investigator believe he/she comply requirement protocol ( e.g . completion diary card , return followup visit ) he/she available schedule visit investigational site . Administration VAC3S past year , Chronic active liver disease , History HCV coinfection ongoing replicate HCV ( positive RTPCR ) HBV ( positive HbS Ag ) coinfection , Any immunotherapy ( e.g . IL2 , IL7 , growth hormone… ) past year exception VAC3S , Any immunosuppressive therapy ( glucocorticoid , cyclosporine , methotrexate ) chronic nonsteroidal antiinflammatory treatment past month , Ongoing pregnancy , Breastfeeding woman , Patient know sensitivity investigational drug ( see please CIB ) , History allergy vaccine , Any severe chronic condition would interfere study , History autoimmune disease , Organ transplant , Splenectomy , Psychiatric disorder significant enough hinder participation assess investigator , Patient participate clinical research trial 30 day precede screen visit ( V1M1 ) . Patients contraindication intramuscular injection include , limited , patient thrombocytopenia and/or anomaly coagulation system , Any uncontrolled chronic acute condition opinion investigator would compromise safety patient ability properly administer study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>